EXHIBIT 99.1
ATHEROGENICS, INC.
(Debtor-in-Possession)
BALANCE SHEET
February 28, 2009
(Unaudited)
| | | | |
| Assets | | |
| Current assets: | | |
| Cash and cash equivalents | $ 47,785,469 | |
| Prepaid expenses | 328,945 | |
| Interest receivable and other current assets | 17,579 | |
| Total current assets | 48,131,993 | |
| | | |
| Equipment and leasehold improvements, net of accumulated depreciation | | |
| and amortization | 703,116 | |
| Total assets | $ 48,835,109 | |
| | | | |
| | | | |
| Liabilities and Shareholders' Deficit | | |
| Current liabilities: | | |
| Accounts payable | $ 50,894 | |
| Accrued compensation | 158,192 | |
| Accrued and other liabilities | 165,150 | |
| Total current liabilities not subject to compromise | 374,236 | |
| | | |
| Prepetition liabilities | 306,680,232 | |
| | | |
| Shareholders' deficit | | |
| Common stock | 218,861,985 | |
| Warrants | 598,172 | |
| Accumulated deficit | (477,679,516 | ) |
| Total shareholders' deficit | (258,219,359 | ) |
| Total liabilities and shareholders' deficit | $ 48,835,109 | |
| | | | |
ATHEROGENICS, INC.
(Debtor-in-Possession)
STATEMENT OF OPERATIONS
For the month ended February 28, 2009
(Unaudited)
| | | |
| Revenues | $ — | |
| | | |
Operating expenses (1): | | |
| Research and development | 687,182 | |
| General and administrative | 424,514 | |
| Total operating expenses | 1,111,696 | |
| | | |
| Operating loss | (1,111,696 | ) |
| Interest and other income | — | |
| Interest expense | — | |
| Net loss before reorganization items | (1,111,696 | ) |
| | | |
| Reorganization items, net | (121,581 | ) |
| | | |
| Net loss | $ (1,233,277 | ) |
| | | |
| Net loss per share – | | |
| basic and diluted | $ (0.03 | ) |
| | | |
| Weighted average shares | | |
| outstanding – basic and diluted | 39,518,492 | |
| | | |
(1) Operating expenses include non-cash depreciation expense of $195,171.
